title: [Early interruption of triple therapy with telaprevir in chronic hepatitis C due to severe adverse effects does not necessarily lead to treatment failure].
authors.affiliation: Servicio de Aparato Digestivo, Hospital Universitario de Girona «Doctor Josep Trueta», Girona, España.
authors.forename: Silvia
authors.initials: S
authors.lastname: Virolés Torrent
authors.affiliation: Servicio de Aparato Digestivo, Hospital Universitario de Girona «Doctor Josep Trueta», Girona, España.
authors.forename: Carmen
authors.initials: C
authors.lastname: López Nuñez
authors.affiliation: Servicio de Aparato Digestivo, Hospital Universitario de Girona «Doctor Josep Trueta», Girona, España.
authors.forename: Manoli
authors.initials: M
authors.lastname: Hombrados Verde
authors.affiliation: Servicio de Aparato Digestivo, Hospital Universitario de Girona «Doctor Josep Trueta», Girona, España.
authors.forename: Montserrat
authors.initials: M
authors.lastname: Figa Francesch
authors.affiliation: Servicio de Análisis Clínicos, Hospital Universitario de Girona «Doctor Josep Trueta», Girona, España.
authors.forename: María José
authors.initials: MJ
authors.lastname: Ferri Iglesias
authors.affiliation: División de Enfermería, Hospital Universitario de Girona «Doctor Josep Trueta», Girona, España.
authors.forename: René
authors.initials: R
authors.lastname: Louvriex Freire
authors.affiliation: Servicio de Aparato Digestivo, Hospital Universitario de Girona «Doctor Josep Trueta», Girona, España. Electronic address: doroteoacero@yahoo.es.
authors.forename: Doroteo
authors.initials: D
authors.lastname: Acero Fernández
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002481:Cellulitis / Q000209:etiology; D003875:Drug Eruptions / Q000209:etiology; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000009:adverse effects* / Q000627:therapeutic use; D010309:Parotitis / Q000209:etiology; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use; D018805:Sepsis / Q000209:etiology; D013203:Staphylococcal Infections / Q000209:etiology; D016896:Treatment Outcome; D028761:Withholding Treatment
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D009842:Oligopeptides; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C486464:telaprevir; C100416:peginterferon alfa-2a